Innoviva (INVA) to Release Earnings on Wednesday

Innoviva (NASDAQ:INVA) is expected to announce its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Innoviva to post earnings of $0.4360 per share and revenue of $110.9850 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:00 PM ET.

Innoviva (NASDAQ:INVA) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.01. The business had revenue of $97.99 million during the quarter, compared to the consensus estimate of $101.57 million. Innoviva had a return on equity of 33.33% and a net margin of 119.89%. On average, analysts expect Innoviva to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Innoviva Stock Performance

INVA stock opened at $21.81 on Wednesday. The stock’s 50 day simple moving average is $22.25 and its 200 day simple moving average is $22.22. Innoviva has a 12-month low of $16.52 and a 12-month high of $25.15. The firm has a market cap of $1.61 billion, a P/E ratio of 3.63 and a beta of 0.34. The company has a current ratio of 21.13, a quick ratio of 20.07 and a debt-to-equity ratio of 0.19.

Analysts Set New Price Targets

A number of brokerages have weighed in on INVA. HC Wainwright reissued a “buy” rating and set a $46.00 target price on shares of Innoviva in a report on Monday, June 1st. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Innoviva in a report on Wednesday, June 24th. BTIG Research reiterated a “buy” rating and set a $42.00 price objective on shares of Innoviva in a research note on Monday, June 22nd. Finally, Wall Street Zen raised shares of Innoviva from a “hold” rating to a “buy” rating in a report on Saturday, June 6th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $36.20.

Hedge Funds Weigh In On Innoviva

Several hedge funds and other institutional investors have recently made changes to their positions in INVA. Invesco Ltd. grew its holdings in Innoviva by 8.8% in the 4th quarter. Invesco Ltd. now owns 832,635 shares of the biotechnology company’s stock worth $16,644,000 after buying an additional 67,069 shares in the last quarter. Vident Advisory LLC bought a new stake in Innoviva during the 4th quarter valued at $565,000. NewEdge Advisors LLC raised its stake in Innoviva by 79.2% during the 4th quarter. NewEdge Advisors LLC now owns 35,984 shares of the biotechnology company’s stock valued at $719,000 after acquiring an additional 15,899 shares in the last quarter. Empowered Funds LLC acquired a new position in Innoviva during the 4th quarter worth $1,492,000. Finally, Uniplan Investment Counsel Inc. boosted its position in Innoviva by 9.5% during the 4th quarter. Uniplan Investment Counsel Inc. now owns 209,733 shares of the biotechnology company’s stock worth $4,193,000 after acquiring an additional 18,263 shares during the period. 99.12% of the stock is currently owned by institutional investors and hedge funds.

About Innoviva

Innoviva, Inc, incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle.